Clinical trials: Surgical Bleeding
Proliferative Diabetic Retinopathy, Diabetic Traction Retinal Detachment
Prospective Randomized Controlled Study of Intravitreal Injection of Bevacizumab for Proliferative Diabetic Retinopathy
We hypothesized that to reduce the adverse effects of intravitreal bevacizumab on ocular tissue and whole body, intravitreal injection of a low concentration of bevacizumab and conducting vitrectomy shortly after the injection is…
- Conditions
- Proliferative Diabetic Retinopathy, Diabetic Traction Retinal Detachment, Vitreous Hemorrhage
- Trial name
- NCT01854593
- Testing
- Bevacizumab, Vitrectomy
- Where
- Japan
- Volunteers
- 69 people
- Sponsor
- Nihon University
Blood Loss, Surgical
Immunogenicity and Safety Study of rThrombin in Surgical Hemostasis
The objective of this study is to assess the immunogenicity and safety of recombinant Thrombin (rThrombin) in patients with prior rThrombin exposure.
- Trial name
- NCT00813904
- Testing
- rThrombin, 1000 IU/mL
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- ZymoGenetics
Atrial Fibrillation, Pericardial Effusion
Active Clearance of Chest Tubes After Cardiac Surgery: A Prospective Randomized Controlled Study
The purpose of this study is to assess the effectiveness of the PleuraFlow® Active Tube Clearance (ATC) technology in reducing the rate of postoperative atrial fibrillation (POAF) among post cardiac surgery patients and to…
- Conditions
- Atrial Fibrillation, Pericardial Effusion, Pleural Effusion, Hemothorax
- Trial name
- NCT02808897
- Testing
- Standard drainage, Active Tube Clearance drainage
- Where
- 2 sites in Canada
- Volunteers
- 520 people, healthy volunteers welcome
- Sponsor
- Montreal Heart Institute
Significant Bleeding Risk
Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk.
To demonstrate that the efficacy of OCTAPLEX as a reversal agent in patients under Vitamin K Antagonist (VKA) therapy with the need for urgent surgery with significant bleeding risk is clinically non-inferior to that Beriplex®…
- Trial name
- NCT02740335
- Testing
- Octaplex, Beriplex P/N (Kcentra)
- Where
- 86 sites in United States, Belarus and 9 more
- Volunteers
- 208 people
- Sponsor
- Octapharma
Vitreous Hemorrhage
Aflibercept Injection for Proliferative Diabetic Retinopathy
To evaluate the ocular and systemic safety of intravitreal aflibercept injection in patients undergoing Pars Plana Vitrectomy for Proliferative Diabetic Retinopathy.
- Trial name
- NCT01805297
- Testing
- Intravitreal Aflibercept Injection, Standard Vitrectomy
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Oklahoma
Surgical Blood Loss
To Evaluate the Safety and Efficacy of the Saline-coupled Bipolar Sealer in Primary Unilateral Total Knee Arthroplasty
The purpose of this study is to investigate whether the saline-coupled bipolar sealer compared to the unipolar electrocautery provides superior hemostasis in patients undergoing primary unilateral total knee arthroplasty.
- Trial name
- NCT03952546
- Testing
- Saline-coupled Bipolar Sealer, Unipolar electrocautery
- Where
- United States
- Volunteers
- 211 people, healthy volunteers welcome
- Sponsor
- Northwell Health
Hemophilia A
Study Evaluating B-Domain Deleted Recombinant Factor VIII (BDDrFVIII, ReFacto AF) in Patients With Hemophilia A Undergoing Elective Major Surgery
This study will examine the efficacy and safety of ReFacto AF in patients with severe and moderately severe hemophilia A undergoing elective major surgery when administered by either bolus injections (BI) or continuous infusion…
- Trial name
- NCT00243659
- Testing
- ReFacto AF
- Where
- 17 sites in United States, Australia and 6 more
- Volunteers
- 30 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Tranexamic Acid, Burn
TXA Study in Major Burn Surgery
Major surgery can result in blood loss that can require a blood transfusion during and/or after surgery. Tranexamic acid (TXA) is a medication that was first introduced in the 1960's as a treatment for heavy menstrual bleeding.
- Conditions
- Tranexamic Acid, Burn, Major Surgery
- Trial name
- NCT02753816
- Testing
- Tranexamic Acid
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Corewell Health West
Bleeding, Blood Loss, Surgical
PCC vs. FFP for Post Cardiopulmonary Bypass Coagulopathy and Bleeding
This will be the first prospective randomized controlled clinical trial directly comparing Prothrombin Complex Concentrate (PCC) Compared to Fresh Frozen Plasma (FFP) for post cardiopulmonary bypass microvascular bleeding and…
- Conditions
- Bleeding, Blood Loss, Surgical, Cardiovascular Surgical Procedures, Prothrombin Complex Concentrates
- Trial name
- NCT02557672
- Testing
- Prothrombin complex concentrate (Human), Fresh frozen plasma (FFP)
- Where
- United States
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Bleeding Cardiac Surgery Patients
Active-control Randomized Trial Comparing 4-factor Prothrombin Complex Concentrate With Frozen Plasma in Cardiac Surgery
This is a multicenter, active-control randomized, prospective, Phase 3 study in adult cardiac surgery patients. 420 patients were randomized at 12 hospitals.
- Trial name
- FARES-2 (NCT05523297)
- Testing
- Octaplex, Frozen Plasma Product, Human
- Where
- 13 sites in United States, Canada
- Volunteers
- 420 people
- Sponsor
- Octapharma
Hypotension During Surgery, Blood Loss, Surgical
Reducing Hypotensive Anesthesia Use With TXA During Orthognathic Surgery
This prospective study will analyze the need for deliberate hypotensive anesthesia (DHA) during orthognathic surgery when tranexamic acid (TXA) is administered.
- Trial name
- NCT05474027
- Testing
- Avoidance of Deliberate Hypotensive Anesthesia, TRANEXAMIC ACID 1 G in 10 mL INTRAVENOUS INJECTION, SOLUTION
- Where
- United States
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Hemorrhage
CU Programme of Idarucizumab for Japanese Patients
The objective is to collect the safety data of idarucizumab for patients treated with dabigatran who require rapid reversal of the anticoagulant effects of dabigatran in cases of uncontrolled or life-threatening bleeding or when…
- Trial name
- NCT02831660
- Testing
- idarucizumab
- Where
- Japan
- Volunteers
- 1 people
- Sponsor
- Boehringer Ingelheim
Bleeding Reduction
Biomarker and Thrombogenicity Assessment in Cardiopulmonary Bypass Surgery Utilizing Acute Normovolemic Hemodilution
This study will help enhance current understanding of the impact of Acute Normovolemic Hemodilution (ANH) administration on transfusion requirements post cardiac surgery, the effect of this procedure on coagulation, and platelet…
- Trial name
- TARGET-ANH (NCT03326323)
- Testing
- Acute Normovolemic Hemodilution
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Inova Health Care Services
Bleeding, Surgical Blood Loss
Decreasing Postoperative Blood Loss by Topical vs. Intravenous Tranexamic Acid in Open Cardiac Surgery
The aim is to conduct a double-blinded single-centre randomized controlled clinical trial of application of topical dose of tranexamic acid (TA) versus the usual intravenous TA in patients undergoing cardiac surgery at the…
- Trial name
- DEPOSITION (NCT03376061)
- Testing
- Tranexamic Acid
- Where
- Canada
- Volunteers
- 97 people
- Sponsor
- Population Health Research Institute
Hemorrhage
SURGICEL® Powder in Controlling Mild or Moderate Parenchymal or Soft Tissue Intraoperative Bleeding in Adult Subjects
This is a prospective, single arm, multicentre, multispecialty, post market, clinical study evaluating SURGICEL Powder as an adjunct to achieve haemostasis (control bleeding) when conventional methods of control are impractical…
- Trial name
- NCT03762200
- Testing
- SURGICEL Powder
- Where
- 8 sites in Belgium, United Kingdom
- Volunteers
- 103 people
- Sponsor
- Ethicon, Inc.
Bloodloss, Surgical Procedures, Operative
A Dose-ranging Safety and Efficacy Study of Ecallantide to Reduce Surgical Blood Loss Volume
The purpose of this study is to assess the efficacy and identify the optimal dose(s) of ecallantide in reducing blood loss in subjects undergoing coronary artery bypass surgery including the use of cardio pulmonary bypass.
- Trial name
- CONSERV-1 (NCT00816023)
- Testing
- ecallantide
- Where
- 29 sites in United States, Canada
- Volunteers
- 276 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Congenital Fibrinogen Deficiency
Efficacy and Safety Study of Octafibrin for On-demand Treatment of Acute Bleeding and to Prevent Bleeding During and After Surgery
The purpose of the study is to assess the efficacy and safety of Octafibrin for on-demand treatment of acute bleeding in subjects with congenital fibrinogen deficiency.
- Trial name
- NCT02267226
- Testing
- Octafibrin
- Where
- 12 sites in United States, Bulgaria and 7 more
- Volunteers
- 25 people
- Sponsor
- Octapharma
Blood Loss, Surgical
Efficacy Study of Recombinant Protein (Ecallantide) to Reduce Blood Loss During Primary Coronary Bypass Grafting or Valve Repair/Replacement
The primary objective of this study was to assess the efficacy and safety of 2 dose levels of ecallantide versus placebo in reducing blood loss following cardiopulmonary bypass (CPB), as measured by chest tube drainage during the…
- Trial name
- NCT00448864
- Testing
- Ecallantide
- Where
- 15 sites in United States
- Volunteers
- 75 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Hemorrhage, Surgical, Blood Loss, Surgical
Safe and Timely Antithrombotic Removal - Ticagrelor (STAR-T)
Prospective, multi-center, double-blind, randomized pivotal trial to evaluate the safety and effectiveness of the DrugSorb-Antithrombotic Removal (ATR) system for intraoperative removal of ticagrelor in patients undergoing urgent…
- Conditions
- Hemorrhage, Surgical, Blood Loss, Surgical, Blood Loss, Postoperative, Hemorrhage Postoperative
- Trial name
- STAR-T (NCT04976530)
- Testing
- DrugSorb-ATR system
- Where
- 29 sites in United States, Canada
- Volunteers
- 140 people
- Sponsor
- CytoSorbents, Inc
Congenital Bleeding Disorder, Haemophilia A
Safety and Efficacy of Turoctocog Alfa in Haemophilia A Subjects
This trial is conducted in Asia, Europe, and North and South America. The trial consists of a main trial and a sub-trial. The main trial investigates safety and efficacy of turoctocog alfa (recombinant factor VIII, rFVIII (N8))…
- Trial name
- guardian™1 (NCT00840086)
- Testing
- turoctocog alfa
- Where
- 63 sites in United States, Brazil and 16 more
- Volunteers
- 150 people
- Sponsor
- Novo Nordisk A/S